Clinical Response to Etoposide Plus Carboplatin and Topotecan Chemotherapy in Small Cell Lung Cancer.
10.4046/trd.2003.54.4.415
- Author:
Kyung Hwa PARK
1
;
Gye Jung CHO
;
Jin Young JU
;
Chang Young SON
;
Jeong Ook WI
;
Kyu Sik KIM
;
Yu Il KIM
;
Sung Chul LIM
;
Young Chul KIM
;
Kyung Ok PARK
Author Information
1. Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. kyc0923@chonnam.ac.kr / medkid@empal.com
- Publication Type:Original Article
- Keywords:
Small cell lung cancer;
Etoposide;
Carboplatin;
Topotecan
- MeSH:
Carboplatin*;
Drug Therapy*;
Drug Therapy, Combination;
Etoposide*;
Humans;
Lung;
Neutropenia;
Recurrence;
Small Cell Lung Carcinoma*;
Survival Rate;
Topotecan*
- From:Tuberculosis and Respiratory Diseases
2003;54(4):415-428
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: This study assessed the efficacy and toxicity of etoposide and carboplatin(EC) combination regimen as a first line therapy for small cell lung cancer(SCLC), and determined the efficacy and toxicity of topotecan for relapsed SCLC. METHODS: One hundred and ten patients with previously untreated SCLC received etoposide(100mg/m2 i.v., day 1 to 3) and carboplatin(300mg/m2 i.v., day 1) combination chemotherapy every 3 weeks. For patients with relapsed SCLC after EC therapy, topotecan(1.5mg/m2) was administered for 5 consecutive days every 3 weeks. Response rate, survival and toxicity profiles were assessed. Response was recorded as CR(complete remission), PR(partial remission), SD(stable disease) and PD(progressive disease). RESULTS: One hundred and one patients were assessed for response to EC. Overall response rate to EC was 57.4%(CR 15.8%, PR 41.6%) with a time to progression of 10.3 months(median). The toxicity was tolerable and there was no treatment-related death. Twenty one relapsed SCLC patients were treated with topotecan. Of those who relapsed within 3 months of EC(refractory relapse, RR), 15.4%(2/13) showed PR, while of those who relapsed after 3 months(sensitive relapse, SR), 25%(2/8) exhibited PR. Grade 4 neutropenia was noted in 9.5% and 14.3% showed thrombocytopenia(G4). CONCLUSION: The EC regimen showed a moderate response rate for SCLC with minimal toxicity. The use of topotecan for relapsed SCLC warrants further investigation.
